In one of the largest licensing deals in the Australian biotechnology industry, Dimerix (ASX:DXB) has signed an exclusive US licence agreement with Amicus Therapeutics to commercialise its kidney disease drug candidate DMX-200.
Dimerix secures one of the largest licensing deals in Australian biotechnology
May 1, 2025 Australian Biotech
Latest Video
New Stories
-
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News -
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News


